Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data showing its proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback